IPO Issue Details
Issue Price / Price Band₹101 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size1,200 Shares per Lot
Total Issue Size29,46,000 shares (aggregating up to ₹29.75 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital
Exchange / PlatformNSE SME
IPO TypeSME
Subscription OpenWed, 14 May 2025
Subscription CloseFri, 16 May 2025
Anchor AllotmentTue, 13 May 2025
Basis of AllotmentMon, 19 May 2025
Initiation of RefundsTue, 20 May 2025
Credit of Shares to DematMon, 19 May 2025
Listing DateWed, 21 May 2025
UPI Mandate Deadline5:00 PM on 16 May 2025 (Day 3)
Application & Investment Details
Retail — Min (1 Lots)₹1,21,200 — 1200 shares
Retail — Max (13 Lots)₹1,575,600 (13 Lots)
HNI — Min (2 Lots)₹2,42,400 — 2,400 shares
EPS (Pre-IPO)₹4.74
EPS (Post-IPO)₹6.28
P/E Ratio (Pre-IPO)21.29x
P/E Ratio (Post-IPO)16.08x
Net Offer to Public27,98,400 shares (aggregating up to ₹28.26 Cr)
Reserved for Market Maker1,47,600 shares (aggregating up to ₹1.49 Cr)
Pre-IPO Promoter Holding81,70,000 shares
Post-IPO Promoter Holding1,11,16,000 shares
About Accretion Pharmaceuticals Ltd
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.The company also offers contract manufacturing services. The Company manufactures and markets Tablets, Capsules, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), and Oral Powder (Sachet, Dry Syrup).The company also holds ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 certifications, reflecting its dedication to quality and environmental management systems.The company's manufacturing unit is located in Ahmedabad, Sanand, Gujarat.The company has expanded its global footprint, marking its presence in more than 20 countries, including regions in Africa, Southeast Asia, and the Middle East.Product Portfolio and ServicesTablets and Capsules – Covering antibiotics, anti-inflammatory, pain management, cardiovascular, and gastrointestinal medicines.Oral Liquids and Syrups – Used for respiratory, pediatric, and digestive treatments.External Preparations – Including medicated lotions, gels, ointments, and dusting powders for skin care and dermatological treatments.Ayurvedic and Herbal Products – Focused on natural wellness solutions for immunity, digestion, and general health.As of January 2025, the company has 83 employees (including 4 Executive Directors) on its payroll.Competitive Strength:Experienced Promoters and Management Team.Long-standing relationship with clients and suppliers.Focus on providing quality products.Management has built a supply chain and customer relations, creating goodwill and trust.
Objects of the Issue
Accretion Pharmaceuticals Ltd proposes to utilise the net proceeds from the Issue for the following objects:
1
Capital expenditure towards purchase of new equipment/ machineries, etc.
2.70
2
Capital expenditure towards upgradation of existing manufacturing facility
4.66
3
Repayment/prepayme nt of certain borrowings availed by the Company
0.99
4
Funding working capital requirements
14.68
5
General Corporate Purpose
4.43
Shareholding & Lock-in
Pre-IPO Promoter Holding
81,70,000 shares
Post-IPO Promoter Holding
1,11,16,000 shares